ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer
At the European Society of Medical Oncology (ESMO) Virtual Congress [...]
PBRM1 as a biomarker for kidney cancer
In this video interview, Dr Eric Jonasch from MD Anderson [...]
ESMO Virtual 2020: Treatment-free survival after immunotherapy vs. targeted therapy for advanced kidney cancer
Over the past 2 years, the use of combination therapies [...]
ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer
Over the past 2 years, the use of combination therapies [...]
Sapanisertib is tolerable and shows activity in advanced kidney cancer
In a phase I study to look at the safety [...]
GRANT score for predicting disease-free survival in kidney cancer
In this retrospective study conducted at various hospitals in Italy, [...]
First-line treatment of kidney cancer
These two videos with Dr Eric Jonasch from MD Anderson [...]
Gut microbes linked with immunotherapy response in kidney cancer
A recent study published in European Urology had shown that [...]
